A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma
Objective To explore the efficacy, safety, and factors that might influence the efficacy of antiPD-1 antibody-based therapy in advanced hepatocellular carcinoma in the real world. Methods The clinical features, efficacy, and safety in patients with advanced hepatocellular carcinoma who received anti...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2023-03-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.0852 |
| _version_ | 1797858550285860864 |
|---|---|
| author | QIAO Shishi KONG Tiandong YU Dan YANG Zhen PAN Yanfeng ZHAO Lingdi |
| author_facet | QIAO Shishi KONG Tiandong YU Dan YANG Zhen PAN Yanfeng ZHAO Lingdi |
| author_sort | QIAO Shishi |
| collection | DOAJ |
| description | Objective To explore the efficacy, safety, and factors that might influence the efficacy of antiPD-1 antibody-based therapy in advanced hepatocellular carcinoma in the real world. Methods The clinical features, efficacy, and safety in patients with advanced hepatocellular carcinoma who received anti-PD-1 antibody-based therapy were retrospectively analyzed. The survival status was followed-up. Results The objective response and the disease control rate were 21.8% and 76.4%, respectively. The overall incidence of adverse events during treatment was 81.8%, of which the incidence of grade 3/4 adverse events was 14.5%. The incidence of immune-related adverse events was 58.2% and the incidence of grade 3/4 immune-related adverse events was 3.6%, and no treatment-related death was observed. The median PFS of the 55 patients was 5.0 (95%CI: 3.9-6.1) months, and the median OS was 11.4 (95%CI: 6.5-16.3) months. Univariate and multivariate analyses showed that liver function Child-Pugh scores and performance status ECOG score were the influencing factors of the objective response rate and survival. Conclusion In the real world anti-PD-1 antibody-based therapy is safe and effective in patients with advanced hepatocellular carcinoma, in which the performance status ECOG score and liver function Child-Pugh score before treatment are independent prognostic factors influencing survival. |
| first_indexed | 2024-04-09T21:15:10Z |
| format | Article |
| id | doaj.art-71d5246827214e4c978fd2f2c77165df |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-04-09T21:15:10Z |
| publishDate | 2023-03-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-71d5246827214e4c978fd2f2c77165df2023-03-28T11:05:45ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782023-03-0150329329710.3971/j.issn.1000-8578.2023.22.08528578.2023.22.0852A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular CarcinomaQIAO Shishi0KONG Tiandong1YU Dan2YANG Zhen3PAN Yanfeng4ZHAO Lingdi5Department of HBP, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, ChinaDepartment of Oncology, Affiliated Cancer Hospital of Henan University, Zhengzhou 450052, ChinaDepartment of Oncology, Zhengzhou Yihe Hospital, Zhengzhou 450052, ChinaDepartment of HBP, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, ChinaDepartment of HBP, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, ChinaDepartment of Oncology, Henan Cancer Hospital, Zhengzhou 450052, ChinaObjective To explore the efficacy, safety, and factors that might influence the efficacy of antiPD-1 antibody-based therapy in advanced hepatocellular carcinoma in the real world. Methods The clinical features, efficacy, and safety in patients with advanced hepatocellular carcinoma who received anti-PD-1 antibody-based therapy were retrospectively analyzed. The survival status was followed-up. Results The objective response and the disease control rate were 21.8% and 76.4%, respectively. The overall incidence of adverse events during treatment was 81.8%, of which the incidence of grade 3/4 adverse events was 14.5%. The incidence of immune-related adverse events was 58.2% and the incidence of grade 3/4 immune-related adverse events was 3.6%, and no treatment-related death was observed. The median PFS of the 55 patients was 5.0 (95%CI: 3.9-6.1) months, and the median OS was 11.4 (95%CI: 6.5-16.3) months. Univariate and multivariate analyses showed that liver function Child-Pugh scores and performance status ECOG score were the influencing factors of the objective response rate and survival. Conclusion In the real world anti-PD-1 antibody-based therapy is safe and effective in patients with advanced hepatocellular carcinoma, in which the performance status ECOG score and liver function Child-Pugh score before treatment are independent prognostic factors influencing survival.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.0852hepatocellular carcinomaanti-pd-1 antibodyliver functionperformance statusreal world |
| spellingShingle | QIAO Shishi KONG Tiandong YU Dan YANG Zhen PAN Yanfeng ZHAO Lingdi A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma Zhongliu Fangzhi Yanjiu hepatocellular carcinoma anti-pd-1 antibody liver function performance status real world |
| title | A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma |
| title_full | A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma |
| title_fullStr | A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma |
| title_full_unstemmed | A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma |
| title_short | A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma |
| title_sort | real world study of anti pd 1 antibody combination therapy in advanced hepatocellular carcinoma |
| topic | hepatocellular carcinoma anti-pd-1 antibody liver function performance status real world |
| url | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.0852 |
| work_keys_str_mv | AT qiaoshishi arealworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT kongtiandong arealworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT yudan arealworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT yangzhen arealworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT panyanfeng arealworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT zhaolingdi arealworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT qiaoshishi realworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT kongtiandong realworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT yudan realworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT yangzhen realworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT panyanfeng realworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma AT zhaolingdi realworldstudyofantipd1antibodycombinationtherapyinadvancedhepatocellularcarcinoma |